The estimated Net Worth of William Banyai is at least $56.7 Milione dollars as of 3 May 2024. Dr Banyai owns over 798 units of Twist Bioscience Corp stock worth over $15,312,540 and over the last 6 years he sold TWST stock worth over $40,783,918. In addition, he makes $628,117 as Sr. VP of Advanced Devel. e GM of Data Storage & Director at Twist Bioscience Corp.
Sign up
Dr D TWST stock SEC Form 4 insiders trading
Dr has made over 45 trades of the Twist Bioscience Corp stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 798 units of TWST stock worth $29,630 on 3 May 2024.
The largest trade he's ever made was exercising 28,181 units of Twist Bioscience Corp stock on 13 October 2021 worth over $200,367. On average, Dr trades about 6,507 units every 20 days since 2018. As of 3 May 2024 he still owns at least 345,188 units of Twist Bioscience Corp stock.
You can see the complete history of Dr Banyai stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. William Charles Banyai Ph.D. biography
Dr. William Charles Banyai Ph.D. is the Sr. VP of Advanced Devel., GM of Data Storage & Director at Twist Bioscience Corp.
What is the salary of Dr D?
As the Sr. VP of Advanced Devel. e GM of Data Storage & Director of Twist Bioscience Corp, the total compensation of Dr D at Twist Bioscience Corp is $628,117. There are 8 executives at Twist Bioscience Corp getting paid more, with Emily Leproust having the highest compensation of $8,126,160.
How old is Dr D?
Dr D is 66, he's been the Sr. VP of Advanced Devel. e GM of Data Storage & Director of Twist Bioscience Corp since . There are no older and 23 younger executives at Twist Bioscience Corp.
What's Dr D's mailing address?
William's mailing address filed with the SEC is C/O TWIST BIOSCIENCE CORPORATION, 681 GATEWAY BLVD., SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Twist Bioscience Corp
Over the last 6 years, insiders at Twist Bioscience Corp have traded over $141,837,821 worth of Twist Bioscience Corp stock and bought 168,550 units worth $2,482,088 . The most active insiders traders include Fred B Craves, Keith Crandell e Emily M. Leproust. On average, Twist Bioscience Corp executives and independent directors trade stock every 8 days with the average trade being worth of $465,824. The most recent stock trade was executed by Dennis Cho on 6 September 2024, trading 275 units of TWST stock currently worth $10,769.
What does Twist Bioscience Corp do?
at twist bioscience, our expertise is synthetic dna. we have developed a proprietary semiconductor-based synthetic dna manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools, such as oligonucleotides, genes, pathways, chassis and genomes. by synthesizing dna on silicon instead of on traditional 96-well plastic plates, our platform overcomes the current inefficiencies of synthetic dna production, and enables cost-effective, rapid, high-quality and high throughput synthetic gene production. the twist bioscience platform has the potential to greatly accelerate the development of personalized medicine, sustainable chemical production, improved agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. for more information, please visit www.twistbioscience.com .
What does Twist Bioscience Corp's logo look like?
Complete history of Dr Banyai stock trades at Twist Bioscience Corp
Twist Bioscience Corp executives and stock owners
Twist Bioscience Corp executives and other stock owners filed with the SEC include:
-
Emily Leproust,
Chairman of the Board, President, Chief Executive Officer -
James Thorburn,
Chief Financial Officer -
Patrick Finn,
Chief Commercial Officer -
Dr. Emily Marine Leproust Ph.D.,
Co-Founder, Chairman, Pres & CEO -
Patrick Weiss,
Chief Operating Officer -
James M. Thorburn,
Chief Financial Officer -
Dr. Patrick John Finn Ph.D.,
Chief Commercial Officer -
Mark Daniels,
Senior Vice President, Chief Legal Officer, Chief Ethics and Compliance Officer and Secretary -
Dr. William Charles Banyai Ph.D.,
Sr. VP of Advanced Devel., GM of Data Storage & Director -
Jan Johannessen,
Independent Director -
Nelson Chan,
Independent Director -
Robert Ragusa,
Independent Director -
Keith Crandell,
Independent Director -
Robert Chess,
Lead Independent Director -
Xiaoying Mai,
Independent Director -
Nicolas Barthelemy,
Independent Director -
William Banyai,
Director -
Paula Green,
Vice President of Human Resources -
Bill Peck,
Chief Technology Officer -
Erin Smith,
Senior Vice President - Government affairs and Public policy -
Martin Kunz,
Senior Vice President - Operation -
Patrick Weiss,
Chief Operating Officer -
Tracey Mullen M.B.A.,
Sr. VP of Operations -
Paula Green,
Sr. VP of HR -
Dennis Cho,
Sr. VP, Gen. Counsel, Chief Ethics & Compliance Officer -
Kevin B. Yankton,
VP & Chief Accounting Officer -
Mark Daniels Esq.,
Sr. VP, Chief Legal Officer, Chief Ethics & Compliance Officer and Sec. -
Dr. Aaron K. Sato,
Chief Scientific Officer & Chief Scientific Officer of BioPharma -
Siyuan Chen,
Chief Technology Officer -
Adam Laponis,
Chief Financial Officer -
Alpha Fund L.P. Ever,
10% owner -
Fred B Craves,
Director -
Venture Partners Viii, Llca...,
-
Melissa A. Starovasnik,
-
Dennis Cho,
See Remarks -
Kevin Bruce Yankton,
Chief Accounting Officer -
Robert F. Werner,
Chief Accounting Officer